Metabolic characteristics of esophageal carcinoma in a veteran population.

Ratajczak, Theresa; Kumar, Geetika; Albandar, Heidar; Redlien, Parker; Yacyshyn, Sara; Markert, Ronald

doi:10.1200/jco.2016.34.15_suppl.4023

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EC is a rapidly growing cancer with a poor five-year survival rate of <20% [ 4 ]. The biology of EC is hardly understood compared to other cancers and typically shows extremely aggressive clinical features upon diagnosis [ 5 ]. Hence, it is one of the most challenging cancers to treat [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

New 4,5-Diarylimidazol-2-ylidene–iodidogold(I) Complexes with High Activity against Esophageal Adenocarcinoma Cells

Schleser

Ghosh

Hörner

et al. 2023

IJMS

View full text Add to dashboard Cite

Inspired by the vascular-disrupting agent combretastatin A-4 and recently published anticancer active N-heterocyclic carbene (NHC) complexes of Au(I), a series of new iodidogold(I)–NHC complexes was synthesized and characterized. The iodidogold(I) complexes were synthesized by a route involving van Leusen imidazole formation and N-alkylation, followed by complexation with Ag2O, transmetalation with chloro(dimethylsulfide)gold(I) [Au(DMS)Cl], and anion exchange with KI. The target complexes were characterized by IR spectroscopy, 1H and 13C NMR spectroscopy, and mass spectrometry. The structure of 6c was validated via single-crystal X-ray diffraction. A preliminary anticancer screening of the complexes using two esophageal adenocarcinoma cell lines showed promising nanomolar activities for certain iodidogold(I) complexes accompanied with apoptosis induction, as well as c-Myc and cyclin D1 suppression in esophageal adenocarcinoma cells treated with the most promising derivative 6b.

show abstract

Section: Introductionmentioning

confidence: 99%

New 4,5-Diarylimidazol-2-ylidene–iodidogold(I) Complexes with High Activity against Esophageal Adenocarcinoma Cells

Schleser

Ghosh

Hörner

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Superior Anticancer and Antifungal Activities of New Sulfanyl-Substituted Niclosamide Derivatives

Ma,

Veeragoni,

Ghosh

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The approved anthelmintic salicylanilide drug niclosamide has shown promising anticancer and antimicrobial activities. In this study, new niclosamide derivatives with trifluoromethyl, trifluoromethylsulfanyl, and pentafluorosulfanyl substituents replacing the nitro group of niclosamide were prepared (including the ethanolamine salts of two promising salicylanilides) and tested for their anticancer activities against esophageal adenocarcinoma (EAC) cells. In addition, antifungal activity against a panel of Madurella mycetomatis strains, the most abundant causative agent of the neglected tropical disease eumycetoma, was evaluated. The new compounds revealed higher activities against EAC and fungal cells than the parent compound niclosamide. The ethanolamine salt 3a was the most active compound against EAC cells (IC50 = 0.8–1.0 µM), and its anticancer effects were mediated by the downregulation of anti-apoptotic proteins (BCL2 and MCL1) and by decreasing levels of β-catenin and the phosphorylation of STAT3. The plausibility of binding to the latter factors was confirmed by molecular docking. The compounds 2a and 2b showed high in vitro antifungal activity against M. mycetomatis (IC50 = 0.2–0.3 µM) and were not toxic to Galleria mellonella larvae. Slight improvements in the survival rate of G. mellonella larvae infected with M. mycetomatis were observed. Thus, salicylanilides such as 2a and 3a can become new anticancer and antifungal drugs.

show abstract

Metabolic characteristics of esophageal carcinoma in a veteran population.

Cited by 2 publications

References 0 publications

New 4,5-Diarylimidazol-2-ylidene–iodidogold(I) Complexes with High Activity against Esophageal Adenocarcinoma Cells

New 4,5-Diarylimidazol-2-ylidene–iodidogold(I) Complexes with High Activity against Esophageal Adenocarcinoma Cells

Superior Anticancer and Antifungal Activities of New Sulfanyl-Substituted Niclosamide Derivatives

Contact Info

Product

Resources

About